• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Vaxess Technologies lands $6m for microneedle vaccines

March 6, 2017 By Sarah Faulkner

Vaxess Technologies said today that it won 2 grants from the Bill & Melinda Gates Foundation totalling up to $6 million for the development of inactivated polio and live attenuated measles rubella vaccines using the company’s Mimix sustained-release microneedle patch technology. The company’s Mimix technology is designed for sustained, transdermal delivery of vaccines and inmmunotherapies, […]

Filed Under: Drug-Device Combinations, Featured, Research & Development, Wall Street Beat Tagged With: Vaxess Technologies

Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution

March 6, 2017 By Sarah Faulkner

Mast Therapeutics subsidiary launches trial for inhaled sodium nitrite solution

Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the company’s AIR001 inhaled sodium nitrite solution in patients with cystic fibrosis. The study will evaluate the nebulized drug as a treatment of Pseudomonas aeruginosa infection in CF […]

Filed Under: Clinical Trials, Featured, Research & Development, Respiratory, Wall Street Beat Tagged With: Mast Therapeutics

AcelRx gains on Q4 earnings

March 3, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results. The Redwood City, Calif.-based company pared its losses to -$9.7 million, or -21¢ per share, on sales of $6.4 million for the 3 months ended Dec. 31, for bottom-line growth of 8.2% on sales growth of […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Wall Street Beat Tagged With: AcelRx

DoD taps BD’s Pyxis for $100m medication dispensing contract

March 3, 2017 By Sarah Faulkner

Becton Dickinson

Becton Dickinson & Co. (NYSE:BDX) said today that it won a $100 million contract from the U.S. Department of Defense for its Pyxis ES system. According to the contract, Franklin Lakes, N.J.-based BD will provide its medication dispensing technology to 115 military inpatient health facilities and military inpatient pharmacies. Get the full story at our sister […]

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: Becton Dickinson, U.S. Department of Defese

Cydar lands Roche exec for 3D imaging software play

March 2, 2017 By Sarah Faulkner

Cydar lands Roche exec for 3D imaging software play

Cydar EV, a medical software start-up, said this week that it hired several new directors, including Roche’s recently-retired chairman Franz Humer. The U.K.-based company is developing cloud-based software to produce 3D images of a patient’s blood vessels in X-ray guided endovascular surgery. Cydar said Humer will bring a “wealth of commercialization” and key developmental insights […]

Filed Under: Featured, Imaging, Technology, Wall Street Beat Tagged With: Cydar EV, Roche

Glenmark, Evestra ink deal to develop generic NuvaRing

March 2, 2017 By Sarah Faulkner

Glenmark, Evestra ink deal to develop generic NuvaRing

Glenmark Pharmaceuticals and Evestra said today that the companies inked a development, license and commercialization deal for a generic version of Merck’s NuvaRing. Development of the etonogestrel/ethinyl estradiol contraceptive is under way, according to the companies, and they plan to file an Abbreviated New Drug Application in fiscal 2019. “This is an important U.S.-based strategic partnership […]

Filed Under: Featured, Research & Development, Wall Street Beat, Women's Health Tagged With: Evestra, Glenmark Pharmaceuticals

Tandem claims 1st remote software update for insulin pump

March 2, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) said today that it released a software update using the company’s Tandem Device Updater tool for its t:slim insulin pumps purchased before April 2015. It marks the 1st time an insulin pump manufacturer has provided a software update that employs customers’ personal computers. The Mac and PC-compatible tool remotely overhauls Tandem’s insulin pump software, […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Technology, Wall Street Beat Tagged With: Tandem Diabetes Care

Aerie resubmits NDA for Rhopressa eye drops

March 1, 2017 By Sarah Faulkner

Aerie

Aerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year, after a contract manufacturer was not prepared for its pre-approval inspection. Aerie’s Rhopressa eye drops specifically target the eye’s trabecular network – the diseased tissue responsible for […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Trump calls for speedier approval process, while Sanders takes aim at drug prices

March 1, 2017 By Sarah Faulkner

Capitol Hill

In his 1st address to Congress, President Donald Trump called for speeding up drug approvals within the FDA. Earlier that day, Sen. Bernie Sanders (I-Vermont) proposed a bill to allow the importation of prescription drugs from Canada in the hopes of lowering drug prices. The new administration has been critical of drug prices, with Trump saying that […]

Filed Under: Featured, Food & Drug Administration (FDA), Policy, Wall Street Beat Tagged With: Capitol Hill

Mylan posts Street-beating Q4 earnings

March 1, 2017 By Sarah Faulkner

Mylan

Shares in Mylan (NSDQ:MYL) rose today after the EpiPen-maker met expectations on Wall Street with its 4th quarter results. The Canonsburg, Pa.-based company posted profits of $417.5 million, or $1.57 per share, on sales of $3.27 billion for the 3 months ended Dec. 31, for bottom-line growth of 114.5% on sales growth of 31.3% compared with the same […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Respiratory, Wall Street Beat Tagged With: Mylan

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 172
  • Page 173
  • Page 174
  • Page 175
  • Page 176
  • Interim pages omitted …
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS